Trial Profile
Real-Life experience regarding hemorragic events and hemostasis tests alterations in Chronic Lymphocytic Leukemia patients treated with ibrutinib.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jan 2017
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 10 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology